Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.61 |
| ▸ | NCS1 | P62166 | 1/20 | 0.60 |
| ▸ | TMPRSS4 | Q9NRS4 | 8/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MYLK | Q15746 | 1/20 | 0.56 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30472744 | 0.91 | CSNK1D (0.62) | DYRK1ATMPRSS4P2RX1P2RX4P2RX7 | |
| SCHEMBL17770389 | 0.91 | CSNK1D (0.62) | DYRK1ATMPRSS4P2RX1P2RX4P2RX7 | |
| Monoethanolamine SCHEMBL19612081 | 0.85 | CSNK1D (0.58) | DYRK1ATMPRSS4P2RX1P2RX4P2RX7 | |
| SCHEMBL19612101 | 0.84 | DYRK1A (0.60) | DYRK1ANCS1DHODHCSNK1D | |
| SCHEMBL19627239 | 0.83 | DYRK1A (0.60) | DYRK1ATMPRSS4P2RX1MEN1KMT2A | |
| SCHEMBL17770342 | 0.82 | DHODH (0.76) | TMPRSS4MEN1KMT2ADHODHCSNK1D | |
| SCHEMBL19612110 | 0.81 | TMPRSS4 (0.57) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL19612095 | 0.81 | TMPRSS4 (0.57) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL19612098 | 0.80 | NCS1 (0.65) | DYRK1ANCS1MAP4K5CSNK1D | |
| SCHEMBL3617783 | 0.79 | DHODH (0.65) | NCS1MEN1KMT2ADHODHKCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-109415363-B | Novel mitochondrial uncoupling agents for the treatment of metabolic diseases and cancer | 罗格斯，新泽西州立大学 | 2021-07-20 | — | — | CN | disclosed |
| EP-3458454-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Rutgers, The State University of New Jersey (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | AK2, PC, GLS2 | DYRK1A 4412/4885NCS1 4216/4885TMPRSS4 3693/4885 |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | AK2, PC, GLS2 | DYRK1A 4289/4885NCS1 4028/4885TMPRSS4 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.